Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a restrospective cohort study in Catalonia, Spain.

dc.contributor.authorFont, Rebeca
dc.contributor.authorEspinàs Piñol, Josep Alfons
dc.contributor.authorGil Gil, Miguel
dc.contributor.authorBarnadas i Molins, Agustí
dc.contributor.authorOjeda, B.
dc.contributor.authorTusquets, Ignasi
dc.contributor.authorSeguí, Miquel A.
dc.contributor.authorMargelí Vila, Mireia
dc.contributor.authorArcusa, Angels
dc.contributor.authorPrat Marín, Andrés
dc.contributor.authorGarcía, M.
dc.contributor.authorBorràs Andrés, Josep Maria
dc.date.accessioned2014-10-30T08:54:39Z
dc.date.available2014-10-30T08:54:39Z
dc.date.issued2012-09-06
dc.date.updated2014-10-30T08:54:39Z
dc.description.abstractAIMS: To compare different methods in order to assess adherence and persistence with oral endocrine therapy in women diagnosed with breast cancer (BC) in Catalonia. MATERIALS AND METHODS: This study covered all women newly diagnosed with stage I, II or IIIa BC and positive hormone receptors at six hospitals in Catalonia (Spain) in 2004. Adherence was assessed on the basis of physician report and patient self-report using a telephone questionnaire. Persistence was measured by refill prescriptions. We used the Kappa index to compare adherence measures and logistic regression to evaluate adherence-related risk factors. RESULTS: The study covered a total of 692 women. Adherence ranged from 92% (self-report) to 94.7% (physician report), depending on the measure used; persistence was 74.7% at 5 years of follow-up. Low concordance between measures was observed (Kappa range: 0.018-0.267). Patients aged 50-74 years showed higher adherence than those aged <50 years. Adherence was also associated with: adjuvant chemotherapy and sequential hormonal therapy. CONCLUSIONS: Concordance between the different measures was remarkably low, indicating the need for further research. Adherence is an issue in the management of BC patients taking oral drugs, and should be assessed in clinical practice.eng
dc.format.extent8 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec626012
dc.identifier.issn0007-0920
dc.identifier.pmid22955858
dc.identifier.urihttps://hdl.handle.net/2445/59206
dc.language.isoeng
dc.publisherCancer Research UK
dc.relation.isformatofReproducció del document publicat a: http://dx.doi.org/10.1038/bjc.2012.389
dc.relation.ispartofBritish Journal of Cancer, 2012, vol. 107, num. 8, p. 1249-1256
dc.relation.urihttp://dx.doi.org/10.1038/bjc.2012.389
dc.rightscc-by-nc-sa (c) Font,R. et al., 2012
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/3.0/es
dc.sourceArticles publicats en revistes (Ciències Clíniques)
dc.subject.classificationCàncer de mamacat
dc.subject.classificationHormonoteràpiacat
dc.subject.classificationCatalunyacat
dc.subject.otherBreast cancereng
dc.subject.otherHormone therapyeng
dc.subject.otherCataloniaeng
dc.titlePrescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a restrospective cohort study in Catalonia, Spain.eng
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
626012.pdf
Mida:
312.1 KB
Format:
Adobe Portable Document Format